Organigram Holdings Inc. (NASDAQ:OGI – Free Report) – Equities researchers at Alliance Global Partners decreased their Q1 2025 earnings estimates for Organigram in a report released on Wednesday, December 18th. Alliance Global Partners analyst A. Grey now expects that the company will post earnings per share of ($0.04) for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Organigram’s current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Organigram’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.11) EPS and FY2026 earnings at ($0.08) EPS.
Organigram (NASDAQ:OGI – Get Free Report) last released its quarterly earnings results on Wednesday, December 18th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Organigram had a negative net margin of 45.57% and a negative return on equity of 16.76%.
Organigram Price Performance
Institutional Investors Weigh In On Organigram
A number of hedge funds have recently bought and sold shares of OGI. Toronto Dominion Bank grew its holdings in Organigram by 803.7% during the 3rd quarter. Toronto Dominion Bank now owns 16,727 shares of the company’s stock worth $30,000 after acquiring an additional 14,876 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Organigram by 40.8% during the second quarter. Renaissance Technologies LLC now owns 816,948 shares of the company’s stock worth $1,258,000 after purchasing an additional 236,700 shares during the last quarter. AdvisorShares Investments LLC grew its stake in Organigram by 11.8% in the second quarter. AdvisorShares Investments LLC now owns 1,000,126 shares of the company’s stock worth $1,540,000 after purchasing an additional 105,468 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in Organigram by 8.3% in the third quarter. Tidal Investments LLC now owns 1,948,188 shares of the company’s stock worth $3,526,000 after purchasing an additional 149,171 shares in the last quarter. Institutional investors and hedge funds own 34.63% of the company’s stock.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Read More
- Five stocks we like better than Organigram
- Dividend Payout Ratio Calculator
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What Are the U.K. Market Holidays? How to Invest and Trade
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.